Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space

The race to the first treatment for non-alcoholic steatohepatitis is packed with contenders—including Madrigal Pharmaceuticals, Hepion Pharmaceuticals and 89Bio—but the recent regulatory failure of Intercept Pharmaceuticals’ obeticholic acid tablets highlights safety concerns in the space.